In comparison with STAD patients in the low-risk subset, five common immune checkpoint molecules had a higher expression in the high-risk subset, but the overexpression of CTLA4 was non-significant (p = 0.075) (Figure 8F–J). This evidence concerns the gene CTLA4 and gastric adenocarcinoma.